Skip to content
Clinical Trials – home

Rheumatologische Schwerpunktpraxis

Research site

Germany Bundesallee 104-105, Friedenau, 12161 Berlin, Germany

  • 4 trials recruiting
  • Psoriatic arthropathy · Rheumatoid arthritis · Axial spondyloarthritis
  • Adult patients

About Specializations

Rheumatologische Schwerpunktpraxis in Berlin, Germany specialises in clinical trials of conditions such as Psoriatic arthropathy, Rheumatoid arthritis, Axial spondyloarthritis, Ankylosing spondylitis, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases

At Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz in Berlin, clinical research in immune system diseases focuses on conditions such as psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, and giant cell arteritis. The trials mainly aim to test new therapies, assess symptom control, and monitor long-term safety in people living with chronic inflammatory disease.

  • Studies in psoriatic arthritis and related inflammatory joint disease
  • Research on rheumatoid arthritis treatment effectiveness and safety
  • Trials in axial spondyloarthritis and flare prevention
  • Evaluation of therapies for giant cell arteritis

This area includes both short-term symptom improvement and longer-term follow-up, with an emphasis on how well treatments work in everyday patients.

Musculoskeletal Diseases

The site conducts a strong portfolio of studies in musculoskeletal diseases, especially rheumatoid arthritis, psoriatic arthritis, and radiographic as well as non-radiographic axial spondyloarthritis. These trials are designed to evaluate whether new treatments can reduce pain, stiffness, and inflammation while improving daily function.

  • Clinical research in rheumatoid arthritis across different levels of disease activity
  • Studies for axial spondyloarthritis, including ankylosing spondylitis
  • Trials measuring improvement in joint symptoms and physical well-being
  • Assessment of treatment response and durability over time

The research reflects a practical focus on therapies that may help patients manage chronic joint disease more effectively.

Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases at this rheumatology specialty practice includes inflammatory conditions with both joint and skin involvement, particularly psoriatic arthritis. The main purpose of these trials is to test new treatment options, compare them with existing therapies, and understand how safely they can be used over time.

  • Focused studies in psoriatic arthritis and active disease control
  • Comparisons of emerging therapies against established treatment options
  • Long-term safety and tolerability research
  • Evaluation of improvements in joint and skin-related symptoms

This research area is especially relevant for patients whose inflammatory disease affects both movement and skin health.

Immune System Processes

A further theme at the Rheumatologische Schwerpunktpraxis is the study of immune system processes involved in chronic inflammation. These trials are aimed at understanding how targeted therapies influence the immune response, with the goal of improving disease control in conditions such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

  • Investigations of immune-targeted treatment approaches
  • Research into reducing inflammation and preventing disease flares
  • Studies of treatment response in chronic autoimmune conditions
  • Ongoing evaluation of safety alongside clinical benefit

The work here helps clarify how newer therapies may better regulate inflammation in patients with long-standing immune-mediated disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Bundesallee 104-105, Friedenau12161 BerlinGermany
Recruiting now
4 trials
Conditions studied
5

More sites in BerlinGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the effectiveness and safety of AZD1163 in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD1163
  • Sponsor:AstraZeneca AB

A Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Rheumatoid arthritis

Not recruiting

Study of SAR441566 and methotrexate in adults with moderate to severe rheumatoid arthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rheumatoid arthritis

Not recruiting

Study of CIT-013 at Three Different Doses for Patients with Moderately Active Rheumatoid Arthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CIT-013
  • Sponsor:Citryll B.V.

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Iqvia Biotech Limited

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.